[Use of HemoCue® or portable hemoglobinometer: results of the national surveys carried out by the SFBC POCT working group].

Hemoglobin (Hb) measurement is a fundamental biological test, especially in emergency situations where rapid medical decisions are required. Portable hemoglobinometers, such as HemoCue®, provide a delocalized solution for capillary whole blood. The SFBC's POCT News and Issues working group designed and conducted two national surveys to assess the use and management of these devices, both on the clinical and biological side, with 306 and 160 responses respectively.

Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.

The pharmacokinetics of rituximab administered alone at a dose of 375 mg/m(2) once a week have been widely studied but few data are available for the administration of rituximab in combination with other agents. We carried out a pilot pharmacokinetic study in 10 patients with B-cell non-Hodgkin lymphoma treated with rituximab associated with chemotherapy on a three-weekly basis. Patients received four courses of rituximab (375 mg/m(2)) associated with CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) at 21-day intervals.